Summit Therapeutics Inc. (SMMT)
USD 27.9
(13.09%)
USD 27.9
(13.09%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 34.67 Million USD | -79.62% |
| 2022 | 170.15 Million USD | 346.57% |
| 2021 | -69 Million USD | -4.64% |
| 2020 | -65.95 Million USD | -4.28% |
| 2019 | -63.24 Million USD | -79.53% |
| 2018 | -35.22 Million GBP | -23.8% |
| 2017 | -28.45 Million GBP | 18.88% |
| 2016 | -35.07 Million GBP | -51.06% |
| 2015 | -23.22 Million GBP | -36.81% |
| 2014 | -16.97 Million GBP | -406.88% |
| 2013 | -3.34 Million GBP | 37.26% |
| 2012 | -5.33 Million GBP | -63.72% |
| 2011 | -3.25 Million GBP | 36.62% |
| 2010 | -5.14 Million GBP | 47.07% |
| 2009 | -9.71 Million GBP | -381.2% |
| 2008 | -2.01 Million GBP | 88.3% |
| 2007 | -17.25 Million GBP | 50.09% |
| 2006 | -34.57 Million GBP | -63.07% |
| 2005 | -21.19 Million GBP | 20.49% |
| 2004 | -26.66 Million GBP | -18167.6% |
| 2003 | -145.95 Thousand GBP | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 48.22 Million USD | 39.09% |
| 2024 Q2 | 79.95 Million USD | 65.78% |
| 2024 Q3 | -69.27 Million USD | -176.64% |
| 2023 Q4 | 34.67 Million USD | -58.16% |
| 2023 Q1 | 33.21 Million USD | -80.48% |
| 2023 Q3 | 82.86 Million USD | 27.21% |
| 2023 Q2 | 65.14 Million USD | 96.13% |
| 2023 FY | 34.67 Million USD | -79.62% |
| 2022 Q4 | 170.15 Million USD | 244.68% |
| 2022 FY | 170.15 Million USD | 346.57% |
| 2022 Q1 | -49.95 Million USD | 27.61% |
| 2022 Q2 | -30.01 Million USD | 39.91% |
| 2022 Q3 | -117.6 Million USD | -291.8% |
| 2021 Q4 | -69 Million USD | 11.99% |
| 2021 Q3 | -78.41 Million USD | 22.54% |
| 2021 Q2 | -101.23 Million USD | -120.91% |
| 2021 Q1 | -45.82 Million USD | 30.52% |
| 2021 FY | -69 Million USD | -4.64% |
| 2020 Q2 | -35.78 Million USD | 33.91% |
| 2020 Q1 | -54.13 Million GBP | -10.04% |
| 2020 Q3 | -20.72 Million USD | 42.08% |
| 2020 Q4 | -65.95 Million USD | -218.27% |
| 2020 FY | -65.95 Million USD | -4.28% |
| 2019 Q4 | -49.19 Million USD | -197.02% |
| 2019 Q3 | -16.56 Million GBP | 31.97% |
| 2019 FY | -63.24 Million USD | -79.53% |
| 2019 Q2 | -24.34 Million GBP | 31.26% |
| 2019 Q1 | -35.41 Million GBP | -0.55% |
| 2018 Q4 | -35.22 Million GBP | -112.51% |
| 2018 Q1 | -38.11 Million GBP | -33.97% |
| 2018 Q2 | -22.49 Million GBP | 40.98% |
| 2018 FY | -35.22 Million GBP | -23.8% |
| 2018 Q3 | -16.57 Million GBP | 26.32% |
| 2017 Q3 | -42.02 Million GBP | -13.03% |
| 2017 Q2 | -37.18 Million GBP | -48.52% |
| 2017 Q1 | -25.03 Million GBP | 28.62% |
| 2017 FY | -28.45 Million GBP | 18.88% |
| 2017 Q4 | -28.45 Million GBP | 32.3% |
| 2016 Q1 | -14.59 Million GBP | 37.13% |
| 2016 FY | -35.07 Million GBP | -51.06% |
| 2016 Q4 | -35.07 Million GBP | 17.06% |
| 2016 Q3 | -42.28 Million GBP | -357.48% |
| 2016 Q2 | -9.24 Million GBP | 36.68% |
| 2015 Q1 | -45.36 Million GBP | -167.3% |
| 2015 Q3 | -34.23 Million GBP | 16.99% |
| 2015 Q4 | -23.22 Million GBP | 32.18% |
| 2015 Q2 | -41.24 Million GBP | 9.09% |
| 2015 FY | -23.22 Million GBP | -36.81% |
| 2014 Q1 | - USD | 100.0% |
| 2014 Q2 | -29.48 Million GBP | 0.0% |
| 2014 FY | -16.97 Million GBP | -406.88% |
| 2014 Q3 | -24.01 Million GBP | 18.56% |
| 2014 Q4 | -16.97 Million GBP | 29.32% |
| 2013 Q2 | -9.14 Million GBP | -52.39% |
| 2013 Q4 | -3.34 Million GBP | 0.0% |
| 2013 FY | -3.34 Million GBP | 37.26% |
| 2013 Q1 | -6 Million USD | -12.49% |
| 2012 FY | -5.33 Million GBP | -63.72% |
| 2012 Q2 | -7.46 Million GBP | -57.1% |
| 2012 Q1 | -4.75 Million USD | -45.83% |
| 2012 Q3 | -3.37 Million USD | 54.76% |
| 2012 Q4 | -5.33 Million GBP | -57.95% |
| 2011 Q3 | -2.07 Million USD | 65.65% |
| 2011 Q4 | -3.25 Million GBP | -57.03% |
| 2011 FY | -3.25 Million GBP | 36.62% |
| 2011 Q2 | -6.04 Million GBP | 0.0% |
| 2010 FY | -5.14 Million GBP | 47.07% |
| 2010 Q4 | -5.14 Million GBP | 0.0% |
| 2010 Q2 | -7.13 Million GBP | 0.0% |
| 2009 Q2 | -1.41 Million GBP | 0.0% |
| 2009 Q4 | -9.71 Million GBP | 0.0% |
| 2009 FY | -9.71 Million GBP | -381.2% |
| 2008 Q4 | -2.01 Million GBP | 0.0% |
| 2008 Q2 | -12.95 Million GBP | 0.0% |
| 2008 FY | -2.01 Million GBP | 88.3% |
| 2007 Q2 | -27.63 Million GBP | 0.0% |
| 2007 Q4 | -17.25 Million GBP | 0.0% |
| 2007 FY | -17.25 Million GBP | 50.09% |
| 2006 Q2 | -36.5 Million GBP | 0.0% |
| 2006 Q4 | -34.57 Million GBP | 0.0% |
| 2006 FY | -34.57 Million GBP | -63.07% |
| 2005 Q2 | -22.66 Million GBP | 0.0% |
| 2005 FY | -21.19 Million GBP | 20.49% |
| 2005 Q4 | -505.18 Thousand GBP | 0.0% |
| 2004 Q4 | -26.66 Million GBP | 0.0% |
| 2004 FY | -26.66 Million GBP | -18167.6% |
| 2004 Q2 | -176.74 Thousand GBP | 0.0% |
| 2003 FY | -145.95 Thousand GBP | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Absci Corporation | -72.59 Million USD | 147.762% |
| Adaptive Biotechnologies Corporation | 164.36 Million USD | 78.905% |
| Alnylam Pharmaceuticals, Inc. | 1.86 Billion USD | 98.146% |
| Alzamend Neuro, Inc. | -75.33 Thousand USD | 46127.026% |
| Apollomics, Inc. | -27.39 Million USD | 226.571% |
| 180 Life Sciences Corp. | -655.73 Thousand USD | 5387.847% |
| Atossa Therapeutics, Inc. | -88.46 Million USD | 139.197% |
| Bicycle Therapeutics plc | -481.46 Million USD | 107.202% |
| Barinthus Biotherapeutics plc | -129.11 Million USD | 126.855% |
| BioXcel Therapeutics, Inc. | 36.16 Million USD | 4.117% |
| CASI Pharmaceuticals, Inc. | 4.15 Million USD | -734.312% |
| Chimerix, Inc. | -25.51 Million USD | 235.886% |
| CRISPR Therapeutics AG | -150.84 Million USD | 122.987% |
| Contineum Therapeutics, Inc. Class A Common Stock | 177.66 Million USD | 80.484% |
| EyePoint Pharmaceuticals, Inc. | -275.79 Million USD | 112.572% |
| Fortress Biotech, Inc. | 7.66 Million USD | -352.368% |
| Fortress Biotech, Inc. | 7.66 Million USD | -352.368% |
| Gritstone bio, Inc. | 39.49 Million USD | 12.195% |
| Allakos Inc. | -24.97 Million USD | 238.835% |
| Boundless Bio, Inc. Common Stock | -21.51 Million USD | 261.192% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 484.583% |
| Cytokinetics, Incorporated | 642.37 Million USD | 94.602% |
| enGene Holdings Inc. Common Stock | -71.74 Million USD | 148.331% |
| Innoviva, Inc. | 255.56 Million USD | 86.432% |
| Hoth Therapeutics, Inc. | -9.23 Million USD | 475.374% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | -4610.719% |
| RAPT Therapeutics, Inc. | -40.57 Million USD | 185.463% |
| Salarius Pharmaceuticals, Inc. | -5.61 Million USD | 718.045% |
| Terns Pharmaceuticals, Inc. | -79.32 Million USD | 143.712% |
| Vigil Neuroscience, Inc. | -38.14 Million USD | 190.908% |
| ImmuCell Corporation | 10.99 Million USD | -215.489% |
| IDEAYA Biosciences, Inc. | -154.14 Million USD | 122.494% |
| Incyte Corporation | -3.17 Billion USD | 101.092% |
| Inovio Pharmaceuticals, Inc. | 15.89 Million USD | -118.098% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 3018.355% |
| Mustang Bio, Inc. | -3.73 Million USD | 1028.105% |
| MiMedx Group, Inc. | -33.9 Million USD | 202.28% |
| MEI Pharma, Inc. | -3.7 Million USD | 1035.87% |
| MacroGenics, Inc. | -66.98 Million USD | 151.764% |
| Monopar Therapeutics Inc. | -7.26 Million USD | 577.204% |
| Mereo BioPharma Group plc | -51.46 Million USD | 167.369% |
| Marker Therapeutics, Inc. | -15.11 Million USD | 329.455% |
| Marinus Pharmaceuticals, Inc. | -10.21 Million USD | 439.475% |
| Maravai LifeSciences Holdings, Inc. | 36 Million USD | 3.697% |
| Minerva Neurosciences, Inc. | 41 Million USD | 15.438% |
| NeuroBo Pharmaceuticals, Inc. | -22.23 Million USD | 255.964% |
| NeuroSense Therapeutics Ltd. | -2.53 Million USD | 1466.194% |
| NextCure, Inc. | -6.47 Million USD | 635.34% |
| Orchestra BioMed Holdings, Inc. | -28.87 Million USD | 220.096% |
| Ocuphire Pharma, Inc. | -50.5 Million USD | 168.66% |
| Onconetix, Inc. | 5.33 Million USD | -550.369% |
| Oncternal Therapeutics, Inc. | -6.37 Million USD | 643.565% |
| Opthea Limited | 28.15 Million USD | -23.143% |
| Ovid Therapeutics Inc. | 18.96 Million USD | -82.878% |
| Psyence Biomedical Ltd. | 6.89 Million USD | -402.915% |
| PDS Biotechnology Corporation | -32.7 Million USD | 206.008% |
| Precigen, Inc. | -481 Thousand USD | 7308.732% |
| Pieris Pharmaceuticals, Inc. | -17.39 Million USD | 299.322% |
| Prime Medicine, Inc. | -27.94 Million USD | 224.097% |
| PureTech Health plc | -167.19 Million USD | 120.738% |
| Rocket Pharmaceuticals, Inc. | -30.86 Million USD | 212.352% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 227.948% |
| Replimune Group, Inc. | 1.41 Million USD | -2355.666% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 389.15% |
| Rigel Pharmaceuticals, Inc. | 27.79 Million USD | -24.758% |
| TransCode Therapeutics, Inc. | -2.31 Million USD | 1596.487% |
| Revolution Medicines, Inc. Warrant | -608.2 Million USD | 105.701% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 287.226% |
| Sesen Bio, Inc. | -112.55 Million USD | 130.807% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 588.366% |
| Solid Biosciences Inc. | -47.75 Million USD | 172.616% |
| Syndax Pharmaceuticals, Inc. | -293.75 Million USD | 111.804% |
| SciSparc Ltd. | -2.06 Million USD | 1779.128% |
| Sutro Biopharma, Inc. | 113.48 Million USD | 69.445% |
| TG Therapeutics, Inc. | 17.86 Million USD | -94.122% |
| Tonix Pharmaceuticals Holding Corp. | -15.13 Million USD | 329.098% |
| Titan Pharmaceuticals, Inc. | -6.2 Million USD | 658.537% |
| Travere Therapeutics, Inc. | 346.6 Million USD | 89.996% |
| UroGen Pharma Ltd. | 4.39 Million USD | -689.661% |
| Verrica Pharmaceuticals Inc. | -24.03 Million USD | 244.253% |
| XOMA Corporation | -29 Million USD | 219.566% |
| Zentalis Pharmaceuticals, Inc. | 17.73 Million USD | -95.512% |
| AbCellera Biologics Inc. | -55.94 Million USD | 161.984% |
| Longboard Pharmaceuticals, Inc. | -13.85 Million USD | 350.245% |
| Cassava Sciences, Inc. | -121.13 Million USD | 128.624% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -397.612% |
| Precision BioSciences, Inc. | -85.41 Million USD | 140.597% |
| Dyadic International, Inc. | -6.37 Million USD | 643.642% |
| Intensity Therapeutics, Inc. | -8.39 Million USD | 512.884% |
| Eton Pharmaceuticals, Inc. | -15.93 Million USD | 317.624% |
| VYNE Therapeutics Inc. | -30.46 Million USD | 213.835% |
| Tenaya Therapeutics, Inc. | -33.25 Million USD | 204.261% |
| IGM Biosciences, Inc. | -72.6 Million USD | 147.756% |
| X4 Pharmaceuticals, Inc. | -41.18 Million USD | 184.191% |
| Acelyrin, Inc. | -216.9 Million USD | 115.986% |
| Abeona Therapeutics Inc. | -9.07 Million USD | 482.167% |
| Ligand Pharmaceuticals Incorporated | -16.78 Million USD | 306.528% |
| Inhibikase Therapeutics, Inc. | -8.54 Million USD | 505.868% |
| Arcturus Therapeutics Holdings Inc. | -316.78 Million USD | 110.945% |
| Syros Pharmaceuticals, Inc. | -77.45 Million USD | 144.769% |
| Senti Biosciences, Inc. | 1.74 Million USD | -1892.759% |
| Mesoblast Limited | 55.96 Million USD | 38.041% |
| Kymera Therapeutics, Inc. | -25.29 Million USD | 237.095% |
| ChromaDex Corporation | -24.04 Million USD | 244.187% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | 4122.091% |
| Akebia Therapeutics, Inc. | 61.25 Million USD | 43.396% |
| Dermata Therapeutics, Inc. | -7.43 Million USD | 566.165% |
| Seer, Inc. | -4.24 Million USD | 917.783% |
| Xeris Biopharma Holdings, Inc. | 161.74 Million USD | 78.562% |
| Novavax, Inc. | -298.29 Million USD | 111.624% |
| Virpax Pharmaceuticals, Inc. | -9.14 Million USD | 479.303% |
| Fate Therapeutics, Inc. | 61.66 Million USD | 43.771% |
| Checkpoint Therapeutics, Inc. | -4.92 Million USD | 803.612% |
| Lyell Immunopharma, Inc. | -82.48 Million USD | 142.039% |
| Celcuity Inc. | 6.78 Million USD | -411.151% |
| ContextLogic Inc. | -232 Million USD | 114.946% |
| Phathom Pharmaceuticals, Inc. | -242.36 Million USD | 114.307% |
| HOOKIPA Pharma Inc. | -110.53 Million USD | 131.369% |
| Jazz Pharmaceuticals plc | 4.59 Billion USD | 99.245% |
| Amarin Corporation plc | -191.04 Million USD | 118.15% |
| AnaptysBio, Inc. | -18.15 Million USD | 291.031% |
| Aptevo Therapeutics Inc. | -11.5 Million USD | 401.33% |
| Aptorum Group Limited | 1.35 Million USD | -2455.109% |
| Cartesian Therapeutics, Inc. | -65.95 Million USD | 152.571% |
| Arrowhead Pharmaceuticals, Inc. | 4.28 Million USD | -710.14% |
| Ardelyx, Inc. | 34.51 Million USD | -0.469% |
| Celularity Inc. | 65.19 Million USD | 46.811% |
| Omeros Corporation | 331.17 Million USD | 89.53% |
| Humacyte, Inc. | -22.48 Million USD | 254.203% |
| Immunocore Holdings plc | -358.59 Million USD | 109.669% |
| IO Biotech, Inc. | -140.69 Million USD | 124.644% |
| GT Biopharma, Inc. | -1.02 Million USD | 3496.082% |
| Cabaletta Bio, Inc. | -188.22 Million USD | 118.422% |
| Alaunos Therapeutics, Inc. | -6.06 Million USD | 671.989% |
| Pulmatrix, Inc. | -10.41 Million USD | 432.86% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 131.125% |
| Evogene Ltd. | -19.63 Million USD | 276.602% |
| CorMedix Inc. | -43.05 Million USD | 180.539% |
| BioLineRx Ltd. | 7.33 Million USD | -372.655% |
| VistaGen Therapeutics, Inc. | -117.04 Million USD | 129.624% |
| Sagimet Biosciences Inc. | -75.07 Million USD | 146.186% |
| PTC Therapeutics, Inc. | -178.97 Million USD | 119.374% |
| scPharmaceuticals Inc. | -6.54 Million USD | 629.778% |
| Fulcrum Therapeutics, Inc. | -14.74 Million USD | 335.206% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 125.609% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | -4610.719% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 287.226% |
| Akero Therapeutics, Inc. | -208.16 Million USD | 116.657% |
| Eliem Therapeutics, Inc. | -92.76 Million USD | 137.379% |
| Lisata Therapeutics, Inc. | -22.28 Million USD | 255.573% |
| Stoke Therapeutics, Inc. | -184.6 Million USD | 118.783% |
| Reneo Pharmaceuticals, Inc. | -26.65 Million USD | 230.065% |
| Outlook Therapeutics, Inc. | 12.16 Million USD | -185.071% |
| ProMIS Neurosciences, Inc. | -16.69 Million USD | 307.726% |
| Daré Bioscience, Inc. | -5.15 Million USD | 772.249% |
| bluebird bio, Inc. | 108.57 Million USD | 68.063% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 90.845% |
| DBV Technologies S.A. | -126.98 Million USD | 127.305% |
| Avidity Biosciences, Inc. | -175.23 Million USD | 119.788% |
| Galecto, Inc. | -21.21 Million USD | 263.433% |
| Sensei Biotherapeutics, Inc. | -6.8 Million USD | 609.687% |
| Spruce Biosciences, Inc. | -91.73 Million USD | 137.8% |
| Inhibrx Biosciences, Inc. | -67.78 Million USD | 151.154% |
| GlycoMimetics, Inc. | -40.98 Million USD | 184.603% |
| Arcutis Biotherapeutics, Inc. | 116.59 Million USD | 70.261% |
| ADMA Biologics, Inc. | 90.06 Million USD | 61.502% |
| Clene Inc. | 3.34 Million USD | -938.144% |
| Recursion Pharmaceuticals, Inc. | -344.12 Million USD | 110.076% |
| Aptose Biosciences Inc. | -8.19 Million USD | 523.119% |
| ZyVersa Therapeutics, Inc. | -3.12 Million USD | 1208.143% |
| Soligenix, Inc. | -4.95 Million USD | 800.259% |
| Century Therapeutics, Inc. | 847 Thousand USD | -3993.743% |
| Kura Oncology, Inc. | -20.11 Million USD | 272.353% |
| Surrozen, Inc. | -32.66 Million USD | 206.154% |
| TScan Therapeutics, Inc. | -40.92 Million USD | 184.724% |
| Ocean Biomedical, Inc. | 1.82 Million USD | -1803.392% |
| CytomX Therapeutics, Inc. | -3.19 Million USD | 1184.579% |
| Autolus Therapeutics plc | -186.59 Million USD | 118.582% |
| Mineralys Therapeutics, Inc. | -49.3 Million USD | 170.327% |
| Eterna Therapeutics Inc. | 34.26 Million USD | -1.185% |
| Caribou Biosciences, Inc. | -23.67 Million USD | 246.446% |
| GRI Bio, Inc. | -1.79 Million USD | 2032.776% |
| Xenetic Biosciences, Inc. | -8.98 Million USD | 485.994% |
| Janux Therapeutics, Inc. | 5.33 Million USD | -549.691% |
| INmune Bio, Inc. | -25.41 Million USD | 236.453% |
| Heron Therapeutics, Inc. | 150.95 Million USD | 77.03% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 168.446% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 313.387% |
| Tenax Therapeutics, Inc. | -9.29 Million USD | 473.191% |
| Jaguar Health, Inc. | 29.39 Million USD | -17.975% |
| Entero Therapeutics, Inc. | -2.88 Million USD | 1301.903% |
| Milestone Pharmaceuticals Inc. | 38.01 Million USD | 8.789% |
| Clearside Biomedical, Inc. | 14.08 Million USD | -146.247% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | -8.747% |
| Coherus BioSciences, Inc. | 377.95 Million USD | 90.826% |
| Verastem, Inc. | -37.27 Million USD | 193.015% |
| Pliant Therapeutics, Inc. | -51.86 Million USD | 166.858% |
| Histogen Inc. | -7.48 Million USD | 563.123% |
| Aprea Therapeutics, Inc. | -21.6 Million USD | 260.477% |
| ACADIA Pharmaceuticals Inc. | -131.45 Million USD | 126.378% |
| Surrozen, Inc. | -32.66 Million USD | 206.154% |
| Organovo Holdings, Inc. | -1.5 Million USD | 2400.863% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 924.886% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.38 Million USD | 513.714% |
| Centessa Pharmaceuticals plc | -43.44 Million USD | 179.817% |
| Hepion Pharmaceuticals, Inc. | -14.57 Million USD | 337.87% |
| BioRestorative Therapies, Inc. | -722.06 Thousand USD | 4902.094% |
| Kronos Bio, Inc. | -36.05 Million USD | 196.172% |
| Turnstone Biologics Corp. | -14.58 Million USD | 337.754% |
| Synaptogenix, Inc. | -28.66 Million USD | 220.978% |
| Tiziana Life Sciences Ltd | -936 Thousand USD | 3804.487% |
| Entrada Therapeutics, Inc. | 628 Thousand USD | -5421.338% |
| Aurinia Pharmaceuticals Inc. | 48.73 Million USD | 28.848% |
| Exelixis, Inc. | -73.05 Million USD | 147.466% |
| Nurix Therapeutics, Inc. | -24.01 Million USD | 244.397% |
| Apellis Pharmaceuticals, Inc. | -241.37 Million USD | 114.365% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 141.229% |
| ESSA Pharma Inc. | -33.62 Million USD | 203.13% |
| TNF Pharmaceuticals, Inc. | -2.63 Million USD | 1417.331% |
| Avid Bioservices, Inc. | 169.72 Million USD | 79.571% |
| Insmed Incorporated | 721.62 Million USD | 95.195% |
| MediWound Ltd. | -5.32 Million USD | 751.522% |
| OmniAb, Inc. | 9.2 Million USD | -276.768% |
| Alector, Inc. | -35.63 Million USD | 197.298% |
| Seres Therapeutics, Inc. | 85.97 Million USD | 59.668% |
| Zai Lab Limited | -775 Million USD | 104.474% |
| AlloVir, Inc. | -62.69 Million USD | 155.308% |
| Revance Therapeutics, Inc. | 340.55 Million USD | 89.818% |
| ORIC Pharmaceuticals, Inc. | -13.17 Million USD | 363.26% |
| Aura Biosciences, Inc. | -21.52 Million USD | 261.087% |
| Immunic, Inc. | -45.34 Million USD | 176.476% |
| Tarsus Pharmaceuticals, Inc. | -193.21 Million USD | 117.946% |
| Veracyte, Inc. | -203.82 Million USD | 117.012% |
| InMed Pharmaceuticals Inc. | 638.29 Million USD | 94.568% |
| FibroGen, Inc. | 56.76 Million USD | 38.919% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | -289.377% |
| Catalyst Pharmaceuticals, Inc. | -134.07 Million USD | 125.861% |
| Adial Pharmaceuticals, Inc. | -2.82 Million USD | 1326.494% |
| Sonnet BioTherapeutics Holdings, Inc. | -2.07 Million USD | 1774.791% |
| Cyclacel Pharmaceuticals, Inc. | -3.34 Million USD | 1137.833% |
| Amylyx Pharmaceuticals, Inc. | -165.96 Million USD | 120.892% |
| Fortrea Holdings Inc. | 1.56 Billion USD | 97.791% |
| KalVista Pharmaceuticals, Inc. | -24.47 Million USD | 241.688% |
| XBiotech Inc. | -200.02 Million USD | 117.335% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 141.229% |
| Keros Therapeutics, Inc. | -316.7 Million USD | 110.948% |
| SELLAS Life Sciences Group, Inc. | -1.72 Million USD | 2111.253% |
| Lyra Therapeutics, Inc. | 4.52 Million USD | -665.769% |
| Foghorn Therapeutics Inc. | -35.26 Million USD | 198.33% |
| Agenus Inc. | 274.13 Million USD | 87.352% |
| Y-mAbs Therapeutics, Inc. | -77.21 Million USD | 144.904% |
| Theravance Biopharma, Inc. | 5.69 Million USD | -509.278% |
| Ultragenyx Pharmaceutical Inc. | -170.41 Million USD | 120.347% |
| Metagenomi, Inc. Common Stock | -92.37 Million USD | 137.537% |
| BioCryst Pharmaceuticals, Inc. | 736.26 Million USD | 95.291% |
| Gain Therapeutics, Inc. | -10.76 Million USD | 422.023% |
| C4 Therapeutics, Inc. | -55.61 Million USD | 162.348% |
| Creative Medical Technology Holdings, Inc. | -3.45 Million USD | 1104.265% |
| Chemomab Therapeutics Ltd. | -8.97 Million USD | 486.295% |
| Lantern Pharma Inc. | -21.7 Million USD | 259.764% |
| Eledon Pharmaceuticals, Inc. | -4.22 Million USD | 919.91% |
| Ainos, Inc. | 4.07 Million USD | -750.285% |
| Pluri Inc. | 22.82 Million USD | -51.886% |
| Prothena Corporation plc | -608.34 Million USD | 105.7% |
| Adaptimmune Therapeutics plc | -118.75 Million USD | 129.198% |
| Rallybio Corporation | -24.1 Million USD | 243.864% |
| Kodiak Sciences Inc. | -103.87 Million USD | 133.381% |
| Cue Biopharma, Inc. | -33.81 Million USD | 202.528% |
| MeiraGTx Holdings plc | -40.3 Million USD | 186.035% |
| Annexon, Inc. | -193.75 Million USD | 117.896% |
| Assembly Biosciences, Inc. | -17.49 Million USD | 298.148% |
| Moderna, Inc. | -2.9 Billion USD | 101.193% |
| Cocrystal Pharma, Inc. | -24.57 Million USD | 241.095% |
| Cidara Therapeutics, Inc. | -30.9 Million USD | 212.21% |
| Blueprint Medicines Corporation | 702.83 Million USD | 95.067% |
| Immix Biopharma, Inc. | -17.5 Million USD | 298.026% |
| CalciMedica, Inc. | -5.53 Million USD | 727.016% |
| Monte Rosa Therapeutics, Inc. | -82.06 Million USD | 142.253% |
| Scholar Rock Holding Corporation | -40.03 Million USD | 186.605% |
| Wave Life Sciences Ltd. | -168.23 Million USD | 120.611% |
| Sana Biotechnology, Inc. | -33.25 Million USD | 204.273% |
| Elicio Therapeutics, Inc. | -5.97 Million USD | 680.124% |
| Adlai Nortye Ltd. American Depositary Shares | -59.94 Million USD | 157.844% |
| Nutriband Inc. | -251.65 Thousand USD | 13878.278% |
| Protara Therapeutics, Inc. | -34.11 Million USD | 201.627% |
| Vor Biopharma Inc. | 4.3 Million USD | -706.372% |
| Roivant Sciences Ltd. | -6.03 Billion USD | 100.574% |
| Alkermes plc | -166.73 Million USD | 120.795% |
| ProKidney Corp. | -56.23 Million USD | 161.658% |
| Applied Therapeutics, Inc. | -48.67 Million USD | 171.24% |
| Arcellx, Inc. | -296.95 Million USD | 111.676% |
| BridgeBio Pharma, Inc. | 1.36 Billion USD | 97.458% |
| Tango Therapeutics, Inc. | -27.46 Million USD | 226.248% |
| Galectin Therapeutics Inc. | 46.14 Million USD | 24.862% |
| Atai Life Sciences N.V. | -28.55 Million USD | 221.416% |
| Renovaro Biosciences Inc. | 2.23 Million USD | -1454.519% |
| Aerovate Therapeutics, Inc. | -22.81 Million USD | 251.972% |
| MediciNova, Inc. | -50.78 Million USD | 168.278% |
| Praxis Precision Medicines, Inc. | -78.8 Million USD | 144.0% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | 154240.92% |
| GeoVax Labs, Inc. | -6.45 Million USD | 637.366% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 117.353% |
| Biomea Fusion, Inc. | -166.57 Million USD | 120.816% |
| RenovoRx, Inc. | -1.17 Million USD | 3056.01% |
| Cullinan Oncology, Inc. | -94.84 Million USD | 136.559% |
| Geron Corporation | 14.76 Million USD | -134.903% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | -659.396% |
| 4D Molecular Therapeutics, Inc. | -234.43 Million USD | 114.79% |
| Dyne Therapeutics, Inc. | -94.21 Million USD | 136.805% |
| Kiniksa Pharmaceuticals, Ltd. | -95.69 Million USD | 136.233% |
| Royalty Pharma plc | 5.65 Billion USD | 99.387% |
| Ventyx Biosciences, Inc. | -39.07 Million USD | 188.742% |
| Imunon, Inc. | -4.21 Million USD | 922.858% |
| BioAtla, Inc. | -109.01 Million USD | 131.808% |
| Allogene Therapeutics, Inc. | 11.96 Million USD | -189.771% |
| Larimar Therapeutics, Inc. | -21.2 Million USD | 263.533% |
| Mersana Therapeutics, Inc. | -140.73 Million USD | 124.638% |
| Structure Therapeutics Inc. | -124.33 Million USD | 127.887% |
| 89bio, Inc. | -289.05 Million USD | 111.996% |
| Kezar Life Sciences, Inc. | -16.56 Million USD | 309.384% |
| aTyr Pharma, Inc. | -7.44 Million USD | 565.485% |
| Aligos Therapeutics, Inc. | -124.63 Million USD | 127.82% |
| Viridian Therapeutics, Inc. | -81.77 Million USD | 142.4% |
| EyeGate Pharmaceuticals, Inc. | -859.18 Thousand USD | 4135.69% |
| Akari Therapeutics, Plc | -3.84 Million USD | 1001.795% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | -2036.559% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 97.489% |
| Lexicon Pharmaceuticals, Inc. | 83.59 Million USD | 58.523% |
| Liquidia Corporation | -80.17 Million USD | 143.247% |
| Entera Bio Ltd. | -10.62 Million USD | 426.221% |
| GH Research PLC | -78.07 Million USD | 144.41% |
| Vericel Corporation | 1.27 Million USD | -2615.27% |
| Arbutus Biopharma Corporation | -17.56 Million USD | 297.415% |
| Xencor, Inc. | 29.64 Million USD | -16.968% |
| 60 Degrees Pharmaceuticals, Inc. | -1.96 Million USD | 1860.27% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 313.387% |
| Coeptis Therapeutics Holdings, Inc. | -244.9 Thousand USD | 14257.97% |
| Vaxcyte, Inc. | -368.22 Million USD | 109.416% |
| Xenon Pharmaceuticals Inc. | -137.74 Million USD | 125.174% |
| Vanda Pharmaceuticals Inc. | -126.41 Million USD | 127.428% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 3018.355% |
| Portage Biotech Inc. | -4.98 Million USD | 796.125% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | 154240.92% |
| Olema Pharmaceuticals, Inc. | -66.12 Million USD | 152.439% |
| OncoCyte Corporation | -6.56 Million USD | 628.325% |
| Qualigen Therapeutics, Inc. | 897.41 Thousand USD | -3763.773% |
| Processa Pharmaceuticals, Inc. | -4.55 Million USD | 861.122% |
| Purple Biotech Ltd. | -14.13 Million USD | 345.254% |
| Tempest Therapeutics, Inc. | -18.56 Million USD | 286.731% |
| Sol-Gel Technologies Ltd. | -5.86 Million USD | 691.706% |
| Rhythm Pharmaceuticals, Inc. | -58.82 Million USD | 158.948% |
| CollPlant Biotechnologies Ltd. | -23.75 Million USD | 245.959% |
| Moleculin Biotech, Inc. | -22.97 Million USD | 250.914% |
| United Therapeutics Corporation | -507.7 Million USD | 106.83% |
| HilleVax, Inc. | -165.48 Million USD | 120.953% |
| Silo Pharma, Inc. | -3.52 Million USD | 1083.853% |
| Telomir Pharmaceuticals, Inc. Common Stock | 99.76 Thousand USD | -34654.282% |
| Pharming Group N.V. | 109.8 Million USD | 68.422% |
| Tharimmune, Inc. | -10.93 Million USD | 417.082% |
| Genprex, Inc. | -6.73 Million USD | 614.632% |
| Apogee Therapeutics, Inc. | -116.28 Million USD | 129.819% |
| Neumora Therapeutics, Inc. Common Stock | -368.8 Million USD | 109.402% |
| Pyxis Oncology, Inc. | 10.19 Million USD | -240.108% |
| XTL Biopharmaceuticals Ltd. | -1.4 Million USD | 2574.946% |
| Virios Therapeutics, Inc. | -3.31 Million USD | 1145.359% |
| OKYO Pharma Limited | -826.84 Thousand USD | 4293.516% |
| Savara Inc. | 153 Thousand USD | -22562.745% |
| Windtree Therapeutics, Inc. | 12.51 Million USD | -177.148% |
| Curis, Inc. | -23.88 Million USD | 245.158% |
| Carmell Therapeutics Corporation | -776.01 Thousand USD | 4568.23% |
| Achieve Life Sciences, Inc. | 1.18 Million USD | -2826.076% |
| BeiGene, Ltd. | -2.25 Billion USD | 101.539% |
| Protagonist Therapeutics, Inc. | -185.58 Million USD | 118.684% |
| Erasca, Inc. | -37.21 Million USD | 193.17% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 2792.304% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 2792.304% |
| Vincerx Pharma, Inc. | -10.35 Million USD | 434.95% |
| Fresh Tracks Therapeutics, Inc. | -10.86 Million USD | 419.047% |
| Acrivon Therapeutics, Inc. Common Stock | -31.37 Million USD | 210.529% |
| Celldex Therapeutics, Inc. | -32.27 Million USD | 207.443% |
| Cogent Biosciences, Inc. | -34.37 Million USD | 200.867% |
| Adicet Bio, Inc. | -138.78 Million USD | 124.984% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 82.494% |
| Aditxt, Inc. | 18.12 Million USD | -91.348% |
| Adagene Inc. | -87.62 Million USD | 139.57% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 932.423% |
| Quantum-Si incorporated | -118.55 Million USD | 129.247% |
| Acurx Pharmaceuticals, Inc. | -7.47 Million USD | 563.917% |
| Voyager Therapeutics, Inc. | -48.5 Million USD | 171.48% |
| Compugen Ltd. | -12.9 Million USD | 368.707% |
| Generation Bio Co. | 31.44 Million USD | -10.258% |
| Astria Therapeutics, Inc. | -175.36 Million USD | 119.773% |
| Black Diamond Therapeutics, Inc. | -30.92 Million USD | 212.13% |
| Invivyd, Inc. | -198.47 Million USD | 117.47% |
| Relay Therapeutics, Inc. | -90.27 Million USD | 138.411% |
| Quoin Pharmaceuticals, Ltd. | -2.39 Million USD | 1546.143% |
| Spero Therapeutics, Inc. | -70.79 Million USD | 148.981% |
| Artelo Biosciences, Inc. | -6.82 Million USD | 608.044% |
| 2seventy bio, Inc. | 181.71 Million USD | 80.918% |
| Instil Bio, Inc. | 75.35 Million USD | 53.988% |
| Capricor Therapeutics, Inc. | -9.08 Million USD | 481.759% |
| Elevai Labs, Inc. Common Stock | -3.11 Million USD | 1212.644% |
| GeoVax Labs, Inc. | -6.45 Million USD | 637.366% |
| Citius Pharmaceuticals, Inc. | -25.99 Million USD | 233.363% |
| Relmada Therapeutics, Inc. | -4.09 Million USD | 947.45% |
| ALX Oncology Holdings Inc. | -5.2 Million USD | 765.656% |
| Vir Biotechnology, Inc. | -130.3 Million USD | 126.61% |
| Evaxion Biotech A/S | 5.28 Million USD | -555.854% |
| Ocular Therapeutix, Inc. | -112.56 Million USD | 130.803% |
| Verve Therapeutics, Inc. | -131.27 Million USD | 126.414% |
| Tyra Biosciences, Inc. | -51.51 Million USD | 167.315% |
| Cingulate Inc. | 3.08 Million USD | -1024.799% |
| Galmed Pharmaceuticals Ltd. | -2.93 Million USD | 1280.592% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -382.454% |
| Connect Biopharma Holdings Limited | -105.54 Million USD | 132.853% |
| Clearmind Medicine Inc. | -3.94 Million USD | 979.462% |
| Bolt Biotherapeutics, Inc. | 9.4 Million USD | -268.52% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | -2277.982% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 163.908% |
| Madrigal Pharmaceuticals, Inc. | 17.27 Million USD | -100.683% |
| ImmunityBio, Inc. | 618.22 Million USD | 94.391% |
| Korro Bio, Inc. | -132.94 Million USD | 126.082% |
| Kineta, Inc. | -4.54 Million USD | 863.576% |
| BioVie Inc. | -17.73 Million USD | 295.541% |
| Codexis, Inc. | -43.27 Million USD | 180.132% |
| Celularity Inc. | 65.19 Million USD | 46.811% |
| Aileron Therapeutics, Inc. | 74.12 Million USD | 53.219% |
| Crinetics Pharmaceuticals, Inc. | -3.16 Million USD | 1194.162% |
| Virax Biolabs Group Limited | -3.36 Million USD | 1130.448% |
| Cibus, Inc. | -8.07 Million USD | 529.24% |
| IN8bio, Inc. | -16.38 Million USD | 311.569% |
| Adverum Biotechnologies, Inc. | 36 Thousand USD | -96216.667% |
| Avalo Therapeutics, Inc. | -3.51 Million USD | 1087.02% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 96.711% |
| Eyenovia, Inc. | 1.25 Million USD | -2654.743% |
| Puma Biotechnology, Inc. | 26.9 Million USD | -28.876% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 1169.195% |
| Elevation Oncology, Inc. | -19.11 Million USD | 281.368% |
| Xilio Therapeutics, Inc. | -33.24 Million USD | 204.292% |
| Cardiff Oncology, Inc. | -19.5 Million USD | 277.761% |
| Enanta Pharmaceuticals, Inc. | -58.87 Million USD | 158.894% |
| Regulus Therapeutics Inc. | -20.72 Million USD | 267.289% |
| Moolec Science SA | 117.61 Thousand USD | -29380.683% |
| Acumen Pharmaceuticals, Inc. | -38.39 Million USD | 190.299% |
| LAVA Therapeutics N.V. | -37.91 Million USD | 191.445% |
| Atea Pharmaceuticals, Inc. | -141.42 Million USD | 124.518% |
| Compass Therapeutics, Inc. | -22.49 Million USD | 254.141% |
| Greenwich LifeSciences, Inc. | -6.98 Million USD | 596.092% |
| TFF Pharmaceuticals, Inc. | -5.36 Million USD | 746.558% |
| Humacyte, Inc. | -22.48 Million USD | 254.203% |
| PMV Pharmaceuticals, Inc. | -25.24 Million USD | 237.366% |
| Avenue Therapeutics, Inc. | -1.78 Million USD | 2044.7% |
| Genelux Corporation | -6.89 Million USD | 602.595% |
| Trevi Therapeutics, Inc. | -31.05 Million USD | 211.639% |
| Notable Labs, Ltd. | -9.77 Million USD | 454.685% |
| Immunovant, Inc. | -635.22 Million USD | 105.459% |
| Quantum-Si incorporated | -118.55 Million USD | 129.247% |
| DiaMedica Therapeutics Inc. | -4.14 Million USD | 936.93% |
| Vera Therapeutics, Inc. | 8.02 Million USD | -331.967% |
| Acasti Pharma Inc. | -23 Million USD | 250.724% |
| MiNK Therapeutics, Inc. | -3.36 Million USD | 1129.749% |
| Soleno Therapeutics, Inc. | -169.27 Million USD | 120.483% |
| PepGen Inc. | -60.67 Million USD | 157.152% |
| Nuvectis Pharma, Inc. | -19.12 Million USD | 281.292% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | 4122.091% |
| Immuneering Corporation | -54.94 Million USD | 163.109% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 924.886% |
| Belite Bio, Inc | -87.27 Million USD | 139.731% |
| XOMA Corporation | -29 Million USD | 219.566% |
| ARS Pharmaceuticals, Inc. | -70.69 Million USD | 149.046% |
| Bionomics Limited | 227 Million USD | 84.726% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 1468.891% |
| uniQure N.V. | -102.95 Million USD | 133.68% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 932.423% |
| Poseida Therapeutics, Inc. | 40.95 Million USD | 15.328% |
| Forte Biosciences, Inc. | -11.96 Million USD | 389.892% |
| Anebulo Pharmaceuticals, Inc. | -3.09 Million USD | 1220.613% |
| Enlivex Therapeutics Ltd. | 106 Thousand USD | -32611.321% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 1169.195% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | -289.377% |
| FibroBiologics, Inc. Common Stock | -7.41 Million USD | 567.557% |
| Altimmune, Inc. | -134.48 Million USD | 125.782% |
| LENZ Therapeutics, Inc. | -185.49 Million USD | 118.692% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 1468.891% |
| Peak Bio, Inc. | 10.34 Million USD | -235.333% |
| Zevra Therapeutics, Inc. | -283 Thousand USD | 12352.297% |
| Benitec Biopharma Inc. | -50.58 Million USD | 168.55% |
| Spyre Therapeutics, Inc. | -104.33 Million USD | 133.232% |
| NKGen Biotech, Inc. Common Stock | 19.64 Million USD | -76.503% |
| Zura Bio Limited | -99.8 Million USD | 134.741% |
| PolyPid Ltd. | 6.17 Million USD | -461.977% |
| NKGen Biotech, Inc. Warrants | 19.64 Million USD | -76.503% |
| argenx SE | -2.02 Billion USD | 101.709% |
| Immunome, Inc. | -97.02 Million USD | 135.736% |
| Verona Pharma plc | -220.44 Million USD | 115.729% |
| enGene Holdings Inc. Warrants | -71.74 Million USD | 148.331% |
| Shattuck Labs, Inc. | -121.42 Million USD | 128.556% |
| CervoMed Inc. | -7.79 Million USD | 544.947% |
| Plus Therapeutics, Inc. | -4.37 Million USD | 892.911% |
| Dianthus Therapeutics, Inc. | -131.73 Million USD | 126.32% |
| Moolec Science SA | 117.61 Thousand USD | -29380.683% |
| Enveric Biosciences, Inc. | -2.28 Million USD | 1615.487% |
| Design Therapeutics, Inc. | -18.15 Million USD | 291.041% |
| Leap Therapeutics, Inc. | -70.38 Million USD | 149.266% |
| Seelos Therapeutics, Inc. | 11.23 Million USD | -208.707% |
| Achilles Therapeutics plc | -126.92 Million USD | 127.319% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | -2277.982% |
| CG Oncology, Inc. Common stock | -7.44 Million USD | 566.048% |
| Fractyl Health, Inc. Common Stock | 340.19 Million USD | 89.808% |
| Rani Therapeutics Holdings, Inc. | 23.73 Million USD | -46.088% |
| MoonLake Immunotherapeutics | -447.47 Million USD | 107.749% |
| Tourmaline Bio, Inc. | -140.31 Million USD | 124.712% |
| Beam Therapeutics Inc. | -262.72 Million USD | 113.198% |
| Mirum Pharmaceuticals, Inc. | 21.81 Million USD | -58.938% |
| AEON Biopharma, Inc. | -4.88 Million USD | 810.533% |
| Aadi Bioscience, Inc. | -55.86 Million USD | 162.069% |
| Enliven Therapeutics, Inc. | -99.86 Million USD | 134.723% |
| Kiora Pharmaceuticals, Inc. | -2.34 Million USD | 1576.876% |
| NeurAxis, Inc. | 145.7 Thousand USD | -23698.216% |
| Iovance Biotherapeutics, Inc. | -39.02 Million USD | 188.848% |
| Lumos Pharma, Inc. | -28.49 Million USD | 221.693% |
| Opiant Pharmaceuticals, Inc. | -20.77 Million USD | 266.912% |
| Palisade Bio, Inc. | -12.06 Million USD | 387.441% |
| Nutriband Inc. | -251.65 Thousand USD | 13878.278% |
| Taysha Gene Therapies, Inc. | -83.28 Million USD | 141.634% |
| Neurogene Inc. | -131.95 Million USD | 126.277% |
| Kintara Therapeutics, Inc. | -4.9 Million USD | 806.335% |
| CARGO Therapeutics, Inc. Common Stock | -377.19 Million USD | 109.193% |
| Athira Pharma, Inc. | -88.99 Million USD | 138.96% |
| HCW Biologics Inc. | 2.85 Million USD | -1113.788% |
| XOMA Corporation | -29 Million USD | 219.566% |
| Nektar Therapeutics | 210.24 Million USD | 83.507% |
| Arvinas, Inc. | -313.8 Million USD | 111.05% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | -2036.559% |
| Merus N.V. | -192.88 Million USD | 117.977% |
| Omega Therapeutics, Inc. | 59.98 Million USD | 42.196% |
| Quince Therapeutics, Inc. | -6.93 Million USD | 599.769% |
| Rezolute, Inc. | -68.16 Million USD | 150.866% |
| Clene Inc. | 3.34 Million USD | -938.144% |
| Indaptus Therapeutics, Inc. | -13.18 Million USD | 362.941% |
| BeyondSpring Inc. | -13.75 Million USD | 352.083% |
| Synlogic, Inc. | -6.68 Million USD | 618.684% |
| Allarity Therapeutics, Inc. | 1.13 Million USD | -2957.672% |
| Phio Pharmaceuticals Corp. | -8.45 Million USD | 510.101% |
| Peak Bio, Inc. | 10.34 Million USD | -235.333% |
| Werewolf Therapeutics, Inc. | -82.42 Million USD | 142.07% |
| Krystal Biotech, Inc. | -350.23 Million USD | 109.9% |
| Karyopharm Therapeutics Inc. | 124.12 Million USD | 72.065% |
| SpringWorks Therapeutics, Inc. | -168.99 Million USD | 120.518% |
| Lipella Pharmaceuticals Inc. | -3.15 Million USD | 1198.271% |
| MannKind Corporation | 143.89 Million USD | 75.904% |
| Ikena Oncology, Inc. | -109.15 Million USD | 131.766% |
| Cyclerion Therapeutics, Inc. | -7.57 Million USD | 557.984% |
| Gyre Therapeutics, Inc. | -33.1 Million USD | 204.755% |
| Gossamer Bio, Inc. | 180.35 Million USD | 80.775% |
| CohBar, Inc. | -5.93 Million USD | 684.65% |
| Cognition Therapeutics, Inc. | -29.74 Million USD | 216.559% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | -659.396% |
| Legend Biotech Corporation | -949.39 Million USD | 103.652% |
| Mural Oncology plc | -255.84 Million USD | 113.553% |
| Disc Medicine, Inc. | -358.28 Million USD | 109.678% |
| Champions Oncology, Inc. | 4.81 Million USD | -620.574% |
| REGENXBIO Inc. | 54.76 Million USD | 36.689% |
| Ensysce Biosciences, Inc. | -268.9 Thousand USD | 12994.421% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 122.959% |
| Cellectar Biosciences, Inc. | -9.01 Million USD | 484.753% |
| Edgewise Therapeutics, Inc. | -80.68 Million USD | 142.976% |
| Vaxart, Inc. | -8.24 Million USD | 520.75% |
| PharmaCyte Biotech, Inc. | -50.17 Million USD | 169.099% |
| Aldeyra Therapeutics, Inc. | -127.16 Million USD | 127.267% |
| Cellectis S.A. | -43.85 Million USD | 179.065% |
| Longeveron Inc. | -2.9 Million USD | 1292.366% |
| Repare Therapeutics Inc. | -107.85 Million USD | 132.148% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 96.419% |
| Inozyme Pharma, Inc. | 12 Million USD | -188.854% |
| Revolution Medicines, Inc. | -608.2 Million USD | 105.701% |
| Nymox Pharmaceutical Corporation | -1.23 Million USD | 2919.024% |
| Third Harmonic Bio, Inc. | -265.11 Million USD | 113.079% |
| ArriVent BioPharma, Inc. Common Stock | -150.07 Million USD | 123.105% |
| AN2 Therapeutics, Inc. | -15.64 Million USD | 321.602% |
| Anixa Biosciences, Inc. | -740 Thousand USD | 4785.676% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 100.363% |
| Denali Therapeutics Inc. | -74.86 Million USD | 146.315% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 389.15% |
| Veru Inc. | 4.77 Million USD | -625.402% |
| Corvus Pharmaceuticals, Inc. | -11.24 Million USD | 408.323% |
| Cingulate Inc. | 3.08 Million USD | -1024.799% |
| Passage Bio, Inc. | 4.58 Million USD | -656.249% |
| Context Therapeutics Inc. | -14.44 Million USD | 339.961% |
| Exicure, Inc. | 5.84 Million USD | -492.819% |
| Day One Biopharmaceuticals, Inc. | -230.37 Million USD | 115.051% |
| Oramed Pharmaceuticals Inc. | -39.57 Million USD | 187.627% |
| Scinai Immunotherapeutics Ltd. | 15.69 Million USD | -120.98% |
| Nuvalent, Inc. | -335.38 Million USD | 110.339% |
| ABVC BioPharma, Inc. | 1.73 Million USD | -1899.261% |
| Carisma Therapeutics, Inc. | -74.48 Million USD | 146.554% |
| Unicycive Therapeutics, Inc. | -8.89 Million USD | 490.034% |
| OmniAb, Inc. | 9.2 Million USD | -276.768% |
| Anew Medical, Inc. | 1.43 Million USD | -2320.583% |
| Fennec Pharmaceuticals Inc. | 16.38 Million USD | -111.662% |
| Lipocine Inc. | -4.75 Million USD | 829.274% |
| Lexeo Therapeutics, Inc. Common Stock | -109.82 Million USD | 131.571% |
| Nautilus Biotechnology, Inc. | 15.23 Million USD | -127.654% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 168.446% |
| G1 Therapeutics, Inc. | 24.89 Million USD | -39.298% |
| Bellerophon Therapeutics, Inc. | -6.72 Million USD | 615.905% |
| Sage Therapeutics, Inc. | -65.82 Million USD | 152.674% |
| Ocugen, Inc. | -32.52 Million USD | 206.62% |
| Mind Medicine (MindMed) Inc. | -85.57 Million USD | 140.519% |
| Q32 Bio Inc. | -37.94 Million USD | 191.372% |
| Brainstorm Cell Therapeutics Inc. | -628 Thousand USD | 5621.338% |
| Alumis Inc. Common Stock | -13.52 Million USD | 356.294% |
| Equillium, Inc. | -22.39 Million USD | 254.85% |
| Kyverna Therapeutics, Inc. | -25.56 Million USD | 235.615% |
| Coya Therapeutics, Inc. | -32.62 Million USD | 206.275% |
| CNS Pharmaceuticals, Inc. | -247.91 Thousand USD | 14086.245% |
| Dominari Holdings Inc. | 195 Thousand USD | -17681.538% |
| Edesa Biotech, Inc. | -5.26 Million USD | 758.337% |
| vTv Therapeutics Inc. | -8.91 Million USD | 488.853% |
| Bio-Techne Corporation | 267.74 Million USD | 87.05% |
| Agios Pharmaceuticals, Inc. | -16.2 Million USD | 313.918% |
| Harmony Biosciences Holdings, Inc. | -118.09 Million USD | 129.361% |
| Prelude Therapeutics Incorporated | -8.4 Million USD | 512.638% |
| Candel Therapeutics, Inc. | -12.65 Million USD | 374.081% |
| iTeos Therapeutics, Inc. | -245.11 Million USD | 114.146% |
| Nkarta, Inc. | 57.29 Million USD | 39.486% |
| BioCardia, Inc. | 212 Thousand USD | -16255.66% |
| Iterum Therapeutics plc | 13.43 Million USD | -158.029% |